Natus Medical announced today that it entered into a definitive agreement to acquire neurophysiology solution provider Micromed.
Middleton, Wisconsin–based Natus expects the transaction to close in early 2023. The company elected not to disclose the financial terms of the deal. It marks the first transaction made by the company since its $1.2 billion acquisition by the ArchiMed group in July.
“We are pleased to make this first growth-oriented investment as an ArchiMed portfolio company,” said Thomas J. Sullivan, Natus CEO. “The breadth and depth of clinical expertise in Natus and Micromed will enable us to bring exciting innovation to our neuroscience customers and their patients around the globe.”
The company plans to join with Micromed to provide a portfolio of neurodiagnostic and neuromonitoring products and services. Micromed’s offerings include Brain Quick, MyoQuick, NeuroWerk, SleepRT and Moberg. Natus expects those products to enable a strong platform for new product development in a range of areas.
Micromed helps Natus develop in the spaces of electroencephalography (EEG), polysomnography (PSG), electromyography (EMG), and intensive care unit (ICU). In addition, the companies plan to integrate the best aspects of both product portfolios, including backward compatibility.
“Joining the forces of the Natus and Micromed teams with their collective knowledge and passion for neurodiagnostics and neurocritical care, will result in both a more comprehensive product offering and an unrivaled global service and support structure for the benefit of our customers,” said Austin Noll, president and leader of Natus Neuro. “The management of our new Natus Neuro Team will work closely with Micromed management to build upon the Micromed momentum in the European Epilepsy market and the emerging presence of Moberg in the ICU.”